Clorox (NYSE:CLX) Given New $130.00 Price Target at Citigroup

Key Points

• Citigroup has lowered its price target for Clorox from $135.00 to $130.00, maintaining a "neutral" rating on the stock, which indicates a potential upside of 8.53% from its current price.
• Other analysts have also revised their targets, with Goldman Sachs downgrading Clorox to a "sell" rating with a target of $110.00, while Bank of America set a target of $125.00 with a "neutral" rating.
• Clorox recently reported a quarterly earnings per share (EPS) of $2.87, exceeding analyst expectations, and has provided FY 2026 guidance of 5.950-6.30 EPS.

Clorox (NYSE:CLX - Get Free Report) had its target price reduced by investment analysts at Citigroup from $135.00 to $130.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has a "neutral" rating on the stock. Citigroup's price target would indicate a potential upside of 8.53% from the company's current price.

Other analysts have also issued research reports about the stock. The Goldman Sachs Group lowered their target price on shares of Clorox from $115.00 to $110.00 and set a "sell" rating for the company in a research note on Wednesday, October 1st. TD Cowen lowered their target price on shares of Clorox from $120.00 to $117.00 and set a "hold" rating for the company in a research note on Wednesday, October 1st. Bank of America lowered their target price on shares of Clorox from $135.00 to $125.00 and set a "neutral" rating for the company in a research note on Wednesday. Weiss Ratings reiterated a "hold (c)" rating on shares of Clorox in a research note on Saturday, September 27th. Finally, Zacks Research upgraded shares of Clorox from a "strong sell" rating to a "hold" rating in a research report on Monday, September 29th. One investment analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Clorox has a consensus rating of "Reduce" and a consensus target price of $132.54.

Clorox Price Performance

Shares of CLX traded up $0.19 during trading hours on Wednesday, reaching $119.78. The company had a trading volume of 70,721 shares, compared to its average volume of 1,679,317. The firm has a 50 day simple moving average of $122.38 and a 200-day simple moving average of $129.11. The company has a market capitalization of $14.65 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 0.98 and a beta of 0.52. Clorox has a 12-month low of $116.53 and a 12-month high of $171.37. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same period in the previous year, the firm posted $1.82 earnings per share. The company's quarterly revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Research analysts expect that Clorox will post 7.15 earnings per share for the current year.

Insider Transactions at Clorox

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.57% of the company's stock.

Hedge Funds Weigh In On Clorox

A number of hedge funds have recently added to or reduced their stakes in the company. Park Avenue Securities LLC bought a new stake in Clorox during the first quarter worth approximately $258,000. Farther Finance Advisors LLC boosted its position in Clorox by 25.4% during the first quarter. Farther Finance Advisors LLC now owns 5,872 shares of the company's stock worth $869,000 after purchasing an additional 1,190 shares during the period. Pallas Capital Advisors LLC bought a new stake in Clorox during the first quarter worth approximately $647,000. Wealthcare Advisory Partners LLC boosted its position in Clorox by 47.8% during the first quarter. Wealthcare Advisory Partners LLC now owns 2,350 shares of the company's stock worth $346,000 after purchasing an additional 760 shares during the period. Finally, Simplicity Wealth LLC bought a new stake in shares of Clorox in the first quarter valued at approximately $1,048,000. Institutional investors and hedge funds own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.